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Abstract Objective: We previously
demonstrated that upregulation of
renal inducible nitric oxide synthase
(iNOS) is associated with proximal
tubule injury during systemic inﬂam-
mation in humans. In this study we
investigated the short-term effect of
methylene blue (MB), an inhibitor of
the NO pathway, on kidney damage
and function in septic shock patients.
Design and setting: A prospective
clinical study conducted in an in-
tensive care unit. Patients: Nine
patients (four men, ﬁve women, mean
age 71±3years) with conﬁrmed or
suspected bacterial infection and with
refractory septic shock deﬁned as
a mean arterial pressure ≤70mmHg
despite norepinephrine infusion
≥ 0.2µg/kg per minute. Interven-
tions: A 4h continuous intravenous
infusion of 1mg/kg MB per hour.
Measurements and results: The
urinary excretion of NO metabolites
decreased with median 90% (range
75–95%) from baseline to 6h after
MB administration. The ﬁrst 24h
creatinine clearance improvedby 51%
(18–173%) after MB treatment but
was still strongly impaired. During
the ﬁrst 6 h after the start of MB
treatment both the urinary excretion
of cytosolic glutathione S-transferase
A1-1 and P1-1, markers for proximal
and distal tubuledamage,respectively,
decreased by 45% (10–70%) and 70%
(40–85) vs. baseline. After termi-
nation of the MB infusion the NO
metabolites and markers of tubular
injury returned to pretreatment levels.
Conclusions: In septic patients with
refractory shock short-term infusion
of MB is associated with a decrease in
NO production and an attenuation of
the urinary excretion of renal tubular
injury markers.
Keywords Inducible nitric oxide
synthase expression · Acute kidney
injury · Glutathione S-Transferase ·
Nitric oxide metabolites351
Introduction
Refractory septic shock remains the major cause of death
in noncoronary intensive care units, especially when
accompanied by multiple organ failure, with an estimated
mortality rate of 50–60% [1]. The incidence of acute renal
failure in refractory septic shock is approx. 40–50% [2].
Nitric oxide has emerged as an important contributory
factor to the pathogenesis of septic shock. We previously
demonstrated that induction of renal NO is associated
with proximal tubule injury during systemic inﬂammation
in humans [3]. NO stimulates soluble guanylate cyclase
(sGC) by binding to its heme moiety, which generates
cyclic guanosine monophosphate (cGMP) [4]. In the
kidney NO and cGMP production are associated with
lipopolysaccharide-induced renal proximal tubular cell
toxicity [5]. Selective sGC inhibition during septic shock
in rats resulted in an attenuation of renal dysfunction [6],
indicating that blocking sGC may be a potential thera-
peutic strategy to treat septic shock-associated renal
failure.
Methylene blue (MB) binds to sGC, blocks cGMP pro-
duction and has the ability to scavenge NO and to inhibit
NO synthases [7, 8]. Although several controlled and un-
controlled clinical studies showed beneﬁcial effects of MB
on the hemodynamic instability during septic shock (re-
viewed in [9]), there are no studies on the putative protec-
tive renal effects. We examined the short-term effects of
Fig.1 NO metabolites in plasma
and urine and the urinary excre-
tion of tubular injury markers
glutathione S-transferase (GST)
A1-1 and P1-1. NO metabolite
levels in plasma (a, n=9)and
urine (b, n=8) and levels of
GSTA1-1 (c, proximal tubule,
n=8) and GSTP1-1 (d, distal
tubule, n=8) were measured in
urine at various times after MB
administration in septic shock
patients. The urinary excretion
of NO metabolites and GSTs
was corrected for creatinine
excretion. Data are expressed as
median with 25–75% range and
analyzed by analysis of variance
with repeated measures over the
two time periods; * p<0.05vs.
baseline, # p<0.05vs.6hafter
MB treatment
continuousinfusion of low-dose MB (1mg/kg per hour) in
patients with septic shock on urinary excretion of the acute
kidneyinjury markers, cytosolicglutathioneS-transferases
(GSTs) present in proximal tubule (GSTA1-1) and distal
tubule (GSTP1-1) [10].
Material and methods
Patients
Nine patients received a 4h continuous infusion of
1mg/kg per hour MB (1% w/v) provided by the VieCuri
Medical Center pharmacy (for inclusion criteria see Elec-
tronic Supplementary Material, ESM). Arterial blood and
catheterized urine were collected at several time points
during the ﬁrst 24h. Clinical parameters, the severity
of illness using Acute Physiology and Chronic Health
Evaluation II (APACHE II), and Sepsis-Related Organ
Failure Assessment (SOFA) were recorded.
Chemical assays
Biochemical parameters were determined by routine
clinical chemistry. Hemoglobin, methemoglobin, and
bilirubin were measured to assess possible side effects
of MB, such as hemolytic anemia and methemoglobine-352
mia [11–13]. Total amount of the stable NO metabolites,
nitrate and nitrite, measure of NO radicals production,
and the amounts of GSTA1-1 and GSTP1-1 in urine were
assayed as described [3]. The blue color in urine due to
MB excretion did not affect the chemical assays.
Statistical analysis
Values are given as mean±S.E. or as median (25–75%
range) depending on their distribution. Differences be-
tween experimental groups were tested by analysis of
variances for repeated measures. A two-tailed p-value less
than 0.05 was considered statistically signiﬁcant.
Results
Patients
Seven patients ultimately died in the intensive care unit,
one of refractory shock (within 12h) and six patients
because of multiple organ failure. In the latter group
two died within 7 days and the remaining four within
28days after intervention. The mean calculated predicted
mortality rate was 61%, and all patients had at least
three organ failures, reﬂecting a mean SOFA score of
11.1± 0.9. The median stay at the intensive care unit was
16days (range 7–24); the two survivors stayed 89days
(52–121) in hospital. Pathogenic organisms isolated by
culture and site of infection are illustrated in the ESM.
Median C-reactive protein was 178mg/l (118–189); all
patients had lactic acidemia (median 2.7 mmol/l, range
2.1–3.7) and thrombocytopenia (68× 109/l, 50–104). The
median MAP increased slightly by 5mmHg (2–11) from
69 (65–70) at baseline to 74 (68–82) 3h after the start of
Table 1 Kidney function parameters of septic shock patients (n=8)
treated with MB
Median Range
Total urine volume, 0–24h (ml) 495 169–885
Protein excretion, 0–24h (mg/day) 342 245–434
Creatinine clearance (ml/min)
Baseline 8.2 4.2–17.4
24h 10.6* 9.6–14.8
Blood urea nitrogen
Baseline 17.8 10.8–20.0
24h 17.3 10.4–22.5
Fractional excretion of sodium (%)
>2%
Baseline (n=0) – –
24 h (n=3) 3.1 2.6–3.6
<1%
Baseline (n=8) 0.6 0.3–0.7
24 h (n=5) 0.4 0.2–0.5
p<0.05 vs. baseline
MB (p< 0.05) with no change in norepinephrine infusion
rate. Methemoglobinemia or hemolytic anemia did not
develop after MB (data not shown). All MB-treated
patients showed blue-coloring of urine and skin.
MB attenuates NO formation
The concentration NO metabolites in plasma was higher
in septic shock patients than in to healthy volunteers [3]
but did not change after MB administration (Fig. 1a). In
contrast, MB signiﬁcantly attenuated the urinary excretion
of NO metabolites by a median 90% (75–95%, p< 0.05)
from baseline(233µmol/mmol creatinine,112–536)to 6h
(37, 10–87) after the start of MB (Fig. 1b). At 4h the MB
infusion was stopped, after which the median excretion
of urinary NO metabolites increased by 135% (65–795%,
p<0.05) within 6–24h after MB treatment (Fig. 1b).
MB attenuates kidney damage
All patients showed impaired renal function with oliguria
and mild proteinuria (Table1). One patient suffered from
anuria during the ﬁrst day. Six patients required continu-
ous venovenous hemoﬁltration renal replacement therapy
with a ﬂow of 35ml/kg (for median 8.5days, 4–13), of
which 3 during the MB infusion. The creatinine clearance
improved by median 51% (18–173%, p< 0.05) during the
ﬁrst24hafterMBbutwasstillstronglyimpaired(Table1).
The urinary excretion of both GSTA1-1 and GSTP1-1 was
elevated in all septic shock patients, indicating both prox-
imal and distal renal tubule damage. During the ﬁrst 6 h
of MB urinary excretion of GSTA1-1 and GSTP1-1 was
attenuated by median 45% (10–70%) and 70% (40–85%)
vs. baseline (Fig.1c, d, p<0.05). After ending MB infu-
sionurinaryexcretionofGSTA1-1andGSTP1-1increased
again, although not signiﬁcantly (Fig.1c, d).
Discussion
Several clinical studies in septic shock patients have
investigated the effects of MB on the heart, vascular wall,
and lungs [9]. This is the ﬁrst report demonstrating that
MB attenuates kidney damage in human septic shock.
To determine the effect of NO pathway inhibition on
renal damage we examined the urinary excretion of early
tubular injury markers and found that MB inhibited the
NO pathway and preserved the integrity of renal tubules.
After termination of MB infusion these parameters re-
turned to their elevated pretreatment levels. Both plasma
concentrations (more than twofold) and urinary NO
metabolites levels in our septic shock patients were
much higher than in healthy volunteers, as demonstrated
earlier [3]. Hydrocortisone may have inhibited iNOS353
activation, however, the patients received a continuous
infusion of hydrocortisonethat started before MB infusion
and continued during the 24h period. Therefore the
observation that urinary NO metabolite excretion was at-
tenuated only in the ﬁrst 6h after the start of MB suggests
that this effect is not related to steroids. Although urinary
NO metabolite excretion was attenuated, we did not ﬁnd
a reduction in plasma NO metabolites. This is in contrast
with an earlier report, in which patients received a bolus
injection of MB prior to the continuous infusion [14].
Renal failure in septic shock patients is a complex
and multifactorial disease process. During septic shock
the systemic vasodilation increases renal sympathetic
activity and angiotensin concentration which results
in intrarenal vasoconstriction with sodium and water
retention and decreased glomerular ﬁltration rate [2]. We
previously demonstrated that induction of renal iNOS,
constitutively expressed in the kidney [15], is associated
with proximal tubule injury during systemic inﬂammation
in humans [3]. As a result of its active secretory transport
function and role in urine concentration, the proximal
tubule is a susceptible target and often the ﬁrst site of
damage [16]. Therefore inhibition of peroxynitrite forma-
tion from excessively produced NO and superoxide [17]
by MB may be beneﬁcial for the kidney during septic
shock, possibly explained by the local accumulation of
MB in renal proximal tubules [18]. Global hemody-
namic variables can inﬂuence renal function, however,
only a small but statistically signiﬁcant increase was
found for mean arterial pressure, whereas other global
hemodynamic parameters did not change during MB
treatment.
Since the detailed nature of our investigation, ob-
viously these methods are not feasible in a large-scale
clinical intervention study. The most elegant way to
examine the effects of MB would be in a randomized,
placebo-controlled cross-over study. However, with such
critically ill patients this design may be considered un-
ethical. We deliberately chose a subgroup of severe septic
shock patients with a high chance of sepsis-induced renal
damage for two reasons: ﬁrst, this is the group of patients
in which MB is used as a “last resort therapy” and, second,
to demonstrate the putative beneﬁcial effects of MB on
renal damage. With an estimated standard deviation of
36% in urinary GST excretion, 80 patients would be
needed to demonstrate with 80% power a 10% reduction
in renal injury. This number of patients was not feasible
for our investigations. Therefore we decided to determine
the parameters before, during and after MB infusion
during a 24h period, which allows each patient to serve
as own control. Because of the observational nature and
limited size of the present study and the heterogeneity of
the patient population, our ﬁndings warrant conformation
on hard endpoints by a larger clinical trial. However, in
our view, ﬁrst a long-term study is necessary to assess
the safety of chronic MB administration in septic patients
with refractory shock. Promising effects of MB were
found in a trial with vasoplegic patients after cardiac
surgery treated with MB [19], in which a reduction in both
mortality and incidence of renal failure was observed.
In conclusion, short-term infusion of MB in septic pa-
tients with refractory shock, is associated with a decrease
in NO production and an attenuation of the urinary excre-
tion of renal tubular injury markers.
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